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Background: Connective tissue progenitors (CTPs) from native bone marrow (BM) or their culture-expanded progeny, often
referred to as mesenchymal stem/stromal cells, represents a promising strategy for treatment of cartilage injuries. But the carti-
lage regeneration capacity of these cells remains unpredictable because of cell heterogeneity.
Hypothesis: The harvest technique of BM may highly influence stem cell heterogeneity and, thus, cartilage formation because
these cells have distinct spatial localization within BM from the same bone.
Study Design: Controlled laboratory study.
Methods: CTPs obtained from the femur of patients undergoing total hip replacement by 2 harvest techniques—BM aspiration
and BM collection—after bone rasping were immunophenotyped by flow cytometry and evaluated for chondrogenic ability. The
spatial localization of different CTP subsets in BM was verified by immunohistochemistry.
Results: Cells from the BM after rasping were significantly more chondrogenic than the donor-matched aspirate, whereas no
notable difference in their osteogenic or adipogenic potential was observed. The authors then assessed whether distinct immu-
nophenotypically defined CTP subsets were responsible for the different chondrogenic capacity. Cells directly isolated from BM
after rasping contained a higher percentage (mean, 7.2-fold) of CD45–CD2711CD561 CTPs as compared with BM aspirates. The
presence of this subset in the harvested BM strongly correlated with chondrogenic ability, showing that CD2711CD561 cells are
enriched in chondroprogenitors. Furthermore, evaluation of these CTP subsets in BM revealed that CD2711CD561 cells were
localized in the bone-lining regions whereas CD2711CD56– cells were found in the perivascular regions. Since the iliac crest re-
mains a frequent site of BM harvest for musculoskeletal regeneration, the authors also compared the spatial distribution of these
subsets in trabeculae of femoral head and iliac crest and found CD2711CD561 bone-lining cells in both tissues.
Conclusion: Chondrogenically distinct CTP subsets have distinct spatial localization in BM; hence, the harvest technique of BM
determines the efficiency of cartilage formation.
Clinical Relevance: The harvest technique of BM may be of major importance in determining the clinical success of BM mes-
enchymal stem/stromal cells in cartilage repair.
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The limited self-healing capacity of cartilage in adults and
its tendency to develop into osteoarthritis once structurally
damaged have led to the search for therapeutic strategies
for cartilage-related traumas. Over the past years,
connective tissue progenitors (CTPs) from native bone
marrow (BM) and their culture-expanded progeny, often
referred to as mesenchymal stem/stromal cells (MSCs),
represent a promising strategy for treatment of cartilage
injuries.19,23 A few studies have found that culture-
expanded MSCs play a vital role in modulating the BM
microenvironment by supporting hematopoiesis, repairing
tissue, and regulating immune response.15,27 In traditional
protocols, unfractionated cells from different sources, BM
among them, are used as starting populations for culture
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expansion. In this setting, the heterogeneous population of
CTPs in these tissues serves as founding cells that in
culture give rise to progeny called MSCs. The resulting
culture-expanded MSCs are poorly defined and heteroge-
neous.29 MSCs isolated in this indirect way remain the
most predominantly used cell source for cartilage repair
strategies.14,22 These culture-expanded MSCs meet the
minimum criteria recommended by the International Soci-
ety of Cellular Therapy, including adhesion to plastic; tri-
potent differentiation into chondrogenic, osteogenic, and
adipogenic phenotypes; expression of surface markers
CD73, CD90, and CD105 (95% expression); the absence
of hematopoietic markers CD34, CD45, CD14 or C11b,
and CD79a or CD19 (2%); and the absence of HLA class
II molecules.13 However, there is an unpredictable varia-
tion in the quality of cartilage formed by these cells.20,33
This poor characterization and unpredictable potency of
the cells limit their clinical translation in cell therapeutic
applications for cartilage repair.33
The iliac crest has become the standard site of BM har-
vest not only for treatment of hematopoietic malignancies3
but also for derivation of culture-expanded MSCs for tissue
repair.25 Next to the iliac crest, one of the most frequent
sites of BM harvest for MSC derivation is the proximal
femur,2 which is readily accessible to the surgeon for lower
limb arthroplasty or trauma surgery. However, CTP popu-
lations from different bones vary in concentration, preva-
lence, and biological potential of individual colonies.1 As
a result, the performance of culture-expanded MSCs from
different sources can be highly variable. Based on this var-
iation in colony-founding CTPs in different bones and
among individual CTPs in the same bone, the culture-
expanded MSCs that grow as the progeny of the colony-
founding CTPs can be highly variable in functional attrib-
utes. CD271 has been proposed as a marker for colony-
founding CTPs in native tissues.2 BM samples aspirated
from the femoral canal and iliac crest contain CD2711
cells.9
Differences in terms of chondrogenic differentiation
capacity of CTP subsets from human BM have been rarely
investigated. In a study by Tormin et al,30 bone-lining cells
expressed CD271 but not the pericyte marker CD146 and
were present at the immediate vicinity of bone, while peri-
vascular-derived cells expressed CD271 as well as CD146
and were found in more central areas of the BM. However,
functional differences of these subsets were not described.
We previously isolated distinct CTP subsets from human
primary BM and demonstrated that the chondrogenic
potential was greater in CD2711CD561 CTP-derived
MSCs as compared with CD2711CD56– CTP-derived
MSCs, which were poorly chondrogenic.5 Preliminary
data also suggest that these distinct CTP subsets have dif-
ferent localizations in BM: CD2711CD561 cells seem to be
enriched in the bone-lining region, while CD2711CD56– cells
are enriched in the perivascular region.29 Hence, it is likely
that the collection technique of BM might determine the
frequency of these CTP subpopulations, which in turn
will influence the quality of cartilage formed. We chose to
address this issue by comparing the differentiation ability
of CTP-derived MSCs from BM harvested from the same
donor by 2 techniques. Also, we address whether CTPs
derived from different bones and from the same bone
with different harvest techniques shared common or dis-
tinct immunophenotypes and anatomic localizations. We
show that the harvest technique of BM influences the fre-
quency of these distinct subpopulations, which affects their
cartilage-forming ability.
METHODS
Participants, Sample Collection, and Processing
After signed informed consent and approval of the local
ethics committee (Erasmus MC MEC-2015-644) harvested,
BM was were obtained from the femur of 15 donors (age,
50-80 years) undergoing total hip replacement. In each
patient, 2 techniques were used for harvesting of BM
from the intertrochanteric region (Figure 1, A and B).
First, BM was collected by aspiration from the greater tro-
chanter. In brief, after the tractus iliotibialis was opened
and the greater trochanter identified, a heparin-immersed
Jamshidi bone biopsy needle (T-Lok BM; Argon Medical
Devices) was introduced into the trochanteric bone, and
2 syringes (10 mL) with 1 mL of heparin (heparin sodium,
5000 IE/mL; Heparin Leo) were used to aspirate femoral
BM. After aspiration of 5 mL, the needle was repositioned
before the second 5 mL was aspirated. Samples from both
syringes were thoroughly mixed, and we termed it aspi-
rated BM. Second, after osteotomy of the femoral neck
and introduction of the first hand reamer to prepare the
femoral canal for stem implantation, the BM that became
available after rasping was collected into a syringe
(10 mL) filled with 1 mL of heparin. We termed this sample
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rasped BM. Active consent for use of rasped BM is not
required according to the regulations of the Dutch Federa-
tion of Medical Scientific Societies (v 2002, updated 2011),
as the sample falls under the category of leftover materials
after surgery. From every donor, samples were collected
with both harvesting methods and treated as paired
samples.
For the histological study of cell subsets in the iliac crest
and femoral head bone, specimens were collected from dif-
ferent patients (3 patients each; not donor matched) under
ethical approval (06/Q1206/127, National Research Ethics
Committee Yorkshire and Humber–Leeds East).
The samples were processed aseptically, and the sample
volume ranged from 15 to 20 mL for aspirates and 3 to 5 mL
for rasped BM. Undiluted aspirates were passed through
a 100-mm cell strainer, and the rasped BM was diluted 1:1
with phosphate-buffered saline (PBS) and then strained
with a 100-mm strainer. A manual cell count was performed
after red blood cell lysis with 4% acetic acid (Sigma Aldrich).
Subsequently, 2 mL of rasped BM and 4 mL of aspirate were
used for fluorescence-activated cell sorting (FACS) analysis
after red blood cell lysis with ammonium chloride (STEM-
CELL Technologies) and remaining samples were used for
initiation of in vitro MSC cultures or colony-forming unit–
fibroblast (CFU-F) assays.
MSC Expansion
To initiate MSC cultures, cells from BM were seeded at
a density of 25,000 nucleated cells/cm2 (rasped BM) or
50,000 nucleated cells/cm2 (aspirate) in MSC medium con-
taining alpha-MEM (GIBCO), supplemented with 10%
fetal calf serum (FCS), 1 ngmL-1 of FGF2 (AbD Serotec),
25 mgmL-1 of ascorbic acid 2–phosphate (Sigma-Aldrich),
1.5 mgmL-1 of Fungizone, and 50 mgmL-1 of gentamicin.
As BM obtained after rasping contained a mean 6 SD
3.0 6 1.5–fold higher CFU-F than the aspirate (Figure
1), cells from the rasped marrow were seeded at lower den-
sity to initiate MSC cultures. MSCs were isolated by their
ability to adhere to plastic culture flasks. After 24 hours,
nonadherent cells were washed out, and adherent cells
were cultured in standard conditions (5% CO2 at 37C)
for 10 to 14 days. Medium was renewed twice a week.
When MSCs neared confluence, they were detached with
0.05% trypsin and reseeded at a density of 2300 cells/cm2.20
Population-doubling times (in days) were calculated
between passages 1 and 2 (P1 and P2) with the formula
[total number of days in culture 3 ln(2)] / [ln(c2) –
ln(c1)], where c2 is the number of cells harvested at the
time of counting at P2, c1 is the number of cells initially
plated at P1, and ln is a Naperian logarithm (doubling-
Figure 1. Enumeration of bone marrow obtained by aspiration and after rasping. Two methods of bone marrow collection: (A) via
aspiration with Jamshidi needle and (B) after rasping. (C) Line graphs show population-doubling time of paired aspirated and
rasped MSCs between passage 1 and passage 2. n = 6 donors. *P = .006. (D) Paired-sample line graphs showing number of
CFU-Fs derived from 1 million mononuclear cells. n = 6 donors. **P \ .005. (E) Morphology of MSCs in passage 2, derived
from BM obtained by aspiration and after rasping. Scale = 20 mm. (F) Representative flow cytometric histograms showing immu-
nophenotype of passage 2 aspirated and rasped MSCs. asp, aspiration; CFU-F, colony-forming unit–fibroblast; MSC, mesen-
chymal stem/stromal cell; rasp, rasping.
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time computing available from http://www.doubling-time
.com/compute.php).
Isolation and Surface Phenotyping
of Culture-Expanded and Uncultured Cells
After blocking of nonspecific binding with 0.2 mg of polyglobin
(Grifols) per 100,000 culture-expanded MSCs (15 minutes,
4C), cells were stained with antibodies against human
CD45-FITC, CD73-PE, CD90-APC, CD166-APC (all from
BD Biosciences), CD31-FITC (Biolegend), or CD105-FITC
(R&D Systems) and incubated for 15 minutes at 4C. The
cells were then washed twice in FACS buffer containing
PBS supplemented with 0.1% bovine serum albumin
(Sigma-Aldrich) and 0.0005% sodium azide (Sigma-Aldrich)
and analyzed on a FACS Canto II flow cytometer (Becton
Dickinson) and FlowJo software (FlowJo).
CTP enumeration on freshly isolated mononuclear cells
from aspirated and rasped samples was performed by
staining 1,000,000 nucleated cells with CD45-PE, CD56-
FITC, and CD271-APC (Miltenyi Biotech) and DAPI. A
minimum of 500,000 events was acquired and analyzed
with a flow cytometer. To confirm the difference in chon-
drogenic capacity of CD2711CD561 and CD2711CD56–
CTPs, at least 108 Ficoll-isolated BM cells were preen-
riched by magnetic-activated cell sorting with the CD271-
APC microbead kit (Miltenyi Biotec), according to the
instructions provided by the manufacturer. After separa-
tion, unbound cells were collected and used as the negative
fraction. In the next step, magnetic-activated cell sorting–
enriched cells were further stained with CD45-PE and
CD56-FITC and sorted on a FACSAria cell sorter (Becton
Dickinson). FACS-sorted cells were plated and cultured
in gelatin-coated flasks as described previously.5
CFU-F Assays
The prevalence of colony-founding CTPs was measured by
CFU-F assays, as performed by plating paired samples of 1
3 106 BM cells or 500 FACS-sorted cells after red blood cell
lysis with ammonium chloride in 0.1% gelatin–coated T-25
flasks in MSC medium. After 10 to 12 days of culture,
adherent cells were washed twice with PBS, fixed with
methanol (Roth) for 5 minutes at room temperature, air-
dried, and stained with the Giemsa solution (Merck).
CFU-F colonies (consisting at least of 50 cells) were macro-
scopically enumerated.
Trilineage Differentiation
For chondrogenic differentiation, P2 expanded cells were
harvested and centrifuged at 250g for 8 minutes to obtain
pellets of 200,000 cells. These cells fulfilled the MSC crite-
ria shown in Figure 1. The pellets were cultured for 4 to 5
weeks in chondrogenic medium consisting of DMEM–high-
glucose GlutaMAX1 (Gibco), 1:100 insulin–transferrin–
selenous acid (BD Biosciences), 40 mg/mL of L-proline
(Sigma-Aldrich), 1mM sodium pyruvate (Gibco), 10-4M
ascorbic acid 2–phosphate (Sigma-Aldrich), 100nM dexa-
methasone (Sigma-Aldrich), 10 ng/mL of transforming
growth factor b1 (R&D Systems), 1.5 mg/mL of Fungizone,
and 50 mg/mL of gentamicin. Medium was renewed twice
a week. At the end of culture, pellets were fixed in 4% for-
malin and paraffin embedded. After deparaffinization, sec-
tions of each sample were stained with 0.4% thionine
solution (Sigma-Aldrich) or 1% alcian blue solution (pH 1;
Merck) to detect glycosaminoglycans. In selected experi-
ments, chondrogenic scores were derived per the inten-
sity of thionin staining (no staining, 0; weak staining, 1;
strong staining, 2). For quantitative polymerase chain
reaction analysis, cultures derived from freshly sorted
CD2711CD56– and CD2711CD561 cells were induced
to form pellets. After 21 days of culture, gene expression
was quantified as described previously.8
Cells were seeded at 3000 cells/cm2 to induce osteogenic
differentiation and then cultured for 12 to 14 days in an
osteogenic induction medium containing DMEM plus
10% FCS and freshly added 10mM b-glycerophosphate,
0.1mM dexamethasone, and 10-4M L-ascorbic acid
2–phosphate (all from Sigma-Aldrich). Cells were seeded
at 20,000 cells/cm2 to induce adipogenic differentiation and
cultured for 12 to 14 days in adipogenic induction medium
containing DMEM with 10% FCS, supplemented with 1mM
dexamethasone, 0.2mM indomethacin, 0.01 mg/mL of
insulin, and 0.5mM 3-isobutyl-l-methyl-xanthine (all
from Sigma-Aldrich).
Immunofluorescence and Immunohistochemistry
To evaluate the relative topography of CD2711 and CD561
cells in situ, 5-mm sections were cut from EDTA decalcified,
paraffin-embedded trabecular bone from the femoral head
(n = 3). Sections were deparaffinized and washed, and
heat-mediated antigen retrieval was performed. Following
blocking with 10% goat serum (SouthernBiotech), 0.1%
sodium azide, and 0.1% cold fish-skin gelatin (Sigma-
Aldrich), sections were incubated overnight with primary
antibodies against CD271 (0.3 mgmL-1) and CD56 (2
mgmL-1; Abcam) at 4C. An isotype mouse and rabbit IgG
antibody was used as negative control. After washing, sec-
ondary staining was performed with Alexa Fluor 488 anti-
mouse and Alexa Fluor 647 anti-rabbit antibody (Thermo
Fisher) for 90 minutes at room temperature, followed by
mounting in DAPI containing VectaMount HardSet Mount-
ing Medium (Vector Laboratories). Positive staining was
confirmed by intensity and specific localization in compari-
son with the negative control. Images were taken on a confo-
cal microscope (SP5; Leica) equipped with standard argon
lasers and a helium-neon laser (633 nm) with a Hyd detec-
tor and analyzed with Fiji software (LOCI).
To investigate the topography of CD561 cells in the
iliac crest bone as compared with femoral head bone,
immunohistochemical staining was performed. Femoral
head samples were obtained from 3 patients undergoing
hip arthroplasty. The samples were cut in half during sur-
gery, transported to the laboratory in saline, and further
processed within 4 hours. Trabecular bone fragments
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were collected from the iliac crest of 3 patients undergoing
pelvic reconstruction surgery after trauma; none had under-
lying disease and were considered healthy. EDTA-decalci-
fied trabecular bone sections from the femoral head (n =
3) and iliac crest (n = 3) were paraffin embedded, and 5-
mm sections were made. Sections were deparaffinized in
xylene and rehydrated through graded ethanol series to
water. EnVision1 Dual Link System-HRP (DAB1; DAKO)
was used for the staining procedure. Endogenous peroxi-
dase activity was blocked with the Dual Endogenous
Enzyme Block reagent (DAKO) for 10 minutes at room tem-
perature. Primary antibody was incubated for 1 hour at
room temperature with CD271 mouse monoclonal antibody
(1:100, clone NGFR5; Abcam) or CD56 rabbit monoclonal
antibody (1:300, clone EPR2566; Abcam). Secondary anti-
bodies conjugated to horseradish peroxidase–labeled poly-
mer (DAKO) were applied for 30 minutes at room
temperature, followed by staining with 3,3#-diaminobenzi-
dine (DAB1) substrate chromogen (DAKO) and counter-
staining with Harris hematoxylin for 2 to 5 minutes. The
optimal concentration of primary antibody had been deter-
mined in dilution series on test tissue sections. No primary
antibody was used as negative control. Slides were scanned
on Leica Aperio AT2 up to original magnification 320, and
images were captured with an Aperio ImageScope at digital
magnification 103.
Statistical Analysis
Data were analyzed with PASW Statistics 21 (SPSS). The
normal distribution of data was confirmed with the
Kolmogorov-Smirnov test. As data were normally distrib-
uted (see Figure 1, C and D), they are presented as mean
6 SD, and a paired t test was applied. Spearman correlation
was used to establish the relation between chondrogenesis
and number of initially seeded CD2711CD561/– cells,
given that data were not normally distributed. Data were
deemed statistically significant when P \ .05.
RESULTS
Surface Phenotype, Growth Rate,
and Clonogenic Enumeration of MSCs
MSCs were isolated by selective plastic adherence from
paired adult human BM samples (6 donors). The samples
were collected by 2 harvest methods: via aspiration (asp-
MSCs) and after rasping (rasp-MSCs). Rasp-MSCs had
a significantly shorter population-doubling time (1.4 6
0.2 days) as compared with asp-MSCs (2.0 6 0.4 days) (Fig-
ure 1C). Standard CFU-F assay was also performed to
measure the CTP content of donor-matched BM obtained
via aspiration and after rasping. BM obtained after rasp-
ing contained significantly higher numbers (3.0 6 1.5–
fold) of colony-forming MSCs as compared with BM
obtained with aspiration (Figure 1D).
Early-passage cultures (P2) derived from both methods
had an indistinguishable morphology (Figure 1E). The
expression of MSC and hematopoietic markers was
assessed in P3 to confirm their MSC identity. The cultured
cells were positive (.95%) for the MSC markers CD73,
CD90, CD166, and CD105 and negative (\2%) for the
hematopoietic and endothelial markers CD45, CD14, and
CD31, thus confirming their identity (Figure 1F).
Rasp-MSCs Show Improved Chondrogenesis but
Equal Osteogenesis and Adipogenesis vs asp-MSCs
Although MSC cultures derived from BM obtained by aspi-
ration and after rasping are both initiated from the proxi-
mal region in the femur, their functional characteristics
could be different because of the cellular composition of
the starting material and the CTP heterogeneity in this
material. Hence, the tripotent differentiation capacity of
P2 MSC cultures derived from BM obtained by aspiration
and after rasping was investigated by culturing in adipo-
genic, osteogenic, and chondrogenic differentiation condi-
tions. After 12 to 14 days of adipogenic differentiation,
both MSC sources expressed oil red O–positive adipocytes,
with most donors (5 of 7) showing no obvious difference in
the proportion of adipocytes and with a few donors (2 of 7)
showing fewer adipocytes in rasp-MSCs as compared with
asp-MSCs (Figure 2). After 12 to 14 days of osteogenic
induction, polygonal cells were observed characteristic of
osteoblast differentiation that stained positive for mineral-
ized nodules with von Kossa staining. No distinct differ-
ence between asp- and rasp-MSCs was observed in the
proportion of von Kossa–stained nodules (Figure 2).
Chondrogenesis was assessed in pellet cultures on day
28. Of interest, rasp-MSCs were considerably more chon-
drogenic than the asp-MSCs, as they formed larger pellets
that contained cells with chondrocyte morphology, as well
as higher levels of the cartilage matrix components glyco-
saminoglycans and collagen type II (Figure 3).
BM Obtained After Rasping Contains
a Significantly Higher Percentage
of CD45–CD2711CD561 Cells vs Aspirate
We investigated whether the highly enriched chondrogenic
differentiation ability of the rasp-MSCs was due to a differ-
ence in the number of chondroprogenitor cells between
aspirated and rasped BM. For this purpose, potential dif-
ferences in surface receptor expression of CD56 on
CD2711 cells were analyzed on freshly isolated aspirated
and rasped samples. This decision was based on studies
by Battula et al5 showing that CD56 was present on uncul-
tured chondrogenic CTPs while absent on nonchondrogenic
CTPs and that CD271 was the most widely used marker to
detect all CFU-F-forming MSCs in BM. Analysis of cellu-
larity was performed in donor-matched aspirated and
rasped BM by counting of all nucleated cells as well as sep-
arate hematopoietic and nonhematopoietic compartments.
Nucleated cell counts per milliliter of BM were 2 to 3 times
higher in BM obtained after rasping as compared with that
from aspiration. FACS analysis revealed that in both
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Figure 2. Osteogenesis (osteo) and adipogenesis (adipo) in paired aspirated and rasped mesenchymal stem/stromal cell cultures
in passage 2. Representative photomicrographs of (top) oil red O staining of adipocytes (n = 6 donors) and (bottom) von Kossa
staining of mineralized nodules (n = 6 donors). Scale = 50 mm.
Figure 3. Chondrogenesis in paired aspirated and rasped mesenchymal stem/stromal cell cultures in passage 2. (Top) Thionin
staining (glycosaminoglycans) and (bottom) collagen type II immunostaining of representative sections from cartilage pellets
formed with cells from paired bone marrow obtained by aspiration and after rasping (n = 6 donors with 3 pellets per donor) fol-
lowing 4 weeks of chondrogenic induction. Scale = 200 mm.
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sources, the majority of cells were CD451 leukocytes and
about 12% were CD45– nonhematopoietic cells (Appendix
Table A1, available in the online version of this article).
In the next step, DAPI-negative live cells were selected,
followed by gating on CD45– nonhematopoietic cells and
analysis of the expression of CD56 on CD271-expressing cells
(Figure 4A). BM samples obtained after rasping contained
a higher percentage of CD2711 cells than BM aspirate. Per-
centage comparison of CD2711CD561/– cells in the CD45–
fraction of freshly isolated aspirated and rasped BM samples
revealed a median 2.7-times higher percentage of
CD2711CD56– cells (interquartile range, 4.05-1.75; not sig-
nificant) and, most important, a 7.2-times higher percentage
of CD2711CD561 cells (interquartile range, 10-3.125;
P = .007) in the rasped BM than in the paired aspirate (Fig-
ure 4B). When back calculated per 1 mL of rasped and
aspirated BM, this corresponds to medians of 2008 and 398
CD2711CD56– cells as well as 250 and 8 CD2711CD561
cells (absolute number), respectively. In particular,
CD2711CD561 CTPs constitute about 0.0002% to 0.0009%
of CD45– cells in aspirate and 0.002% to 0.004% in rasped
BM.
CD56 Cell Surface Expression in Uncultured,
Freshly Isolated CTPs Predicts Their
Subsequent Chondrogenic Capacity
To determine whether CD56 cell surface marker positivity is
a predictor of chondrogenic capacity, Spearman correlation
coefficients were calculated comparing the chondrogenic
scores (assessed by thionin and collagen II staining) of
Figure 4. Flow cytometric analysis of CD45, CD271, and CD56 expression in freshly isolated mononuclear cells from paired bone
marrow obtained by aspiration and after rasping. (A) After dead cell exclusion with DAPI, CD45– cells were selected, and the
expression of CD56 on CD2711 cells was analyzed. Note that CD56 is expressed on rare CD2711 cells and is enriched in rasped
samples as compared with the aspirate (n = 6 donors). (B) Percentage of CD2711CD561 and CD2711CD56– mesenchymal
stem/stromal cell subsets in the freshly isolated paired aspirate and rasped samples shown in panel A. Relationship between
donor-matched chondrogenic histologic scores and total number of (C) CD2711CD561 cells and (D) CD2711CD56– cells freshly
seeded from corresponding aspirate and rasped samples, by Spearman rank correlation (n = 6 donors). N.S., not significant.
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donor-matched day 28 pellets from P2 expanded MSCs with
the total number of freshly seeded CD45–CD2711CD561 or
CD45–CD2711CD56– cells in the corresponding aspirated
and rasped BM samples. The analyses (n = 6 donors) con-
firmed a very strong positive correlation (Spearman correla-
tion, r = 0.879; P \ .0001) between total number of CD45–
CD2711CD561 cells and chondrogenesis as assessed by his-
tological scores (Figure 4C). There was no correlation (Spear-
man correlation, r = 20.052; P = .872) between total number
of CD45–CD2711CD56– cells and chondrogenesis (Figure
4D). Furthermore, cultured MSCs derived from FACS-sorted
CD45–CD2711CD561 and CD45–CD2711CD56– CTPs (n
= 1; Appendix Figure A1A) revealed that CD45–
CD2711CD561 cells gave rise to more colonies. MSCs
derived from CD561 and CD56– CTPs in P1 expressed clas-
sic MSC markers. CD271 and CD56 were downregulated
after culturing and absent in P1 (Appendix Figure A1, B-
D). Nevertheless, the MSCs derived from CD45–
CD2711CD561 cells had higher chondrogenic differentia-
tion ability as compared with MSCs derived from CD45–
CD2711CD56– cells. To further confirm the increased chon-
drogenic capacity of CD45–CD2711CD561 CTPs, different
CTP subsets (CD45–CD2711CD56– and CD45–
CD2711CD561 cells) were isolated from the femoral trabec-
ulae of 3 donors by FACS sorting, in vitro expanded, chondro-
genically differentiated, and analyzed for expression of
chondrogenic genes. CD561 cells showed higher COL2A1
and SOX9 levels after 21 days of chondrogenesis as compared
with CD56– cells (Appendix Figure A1E). These results dem-
onstrate the direct contribution of CD45–CD2711CD561
CTPs to improved chondrogenesis.
CD2711CD561 and CD2711CD56– Subsets Have
Distinct Spatial Localization in Femur and Iliac Crest
To investigate the in situ localization of CD2711CD561
and CD2711CD56– cells, paraffin-embedded sections of
human iliac crest and femoral head trabecular bone biopsy
specimens were single stained with monoclonal antibodies
against human CD271 or CD56. DAB-peroxidase staining
revealed that CD271 expression was present as expected
Figure 5. In situ distribution of CD2711 and CD561 cells in
bone marrow from femoral head and iliac crest bone. Paraffin
sections of human bone marrow biopsy specimens were single
stained with antibodies against CD271 and CD56. In both fem-
oral head and iliac crest, CD2711 cells were localized in peri-
vascular (arrows) and bone-lining (arrowheads) regions, while
CD561 cells were detected in only the bone-lining region
(arrowheads) and not in the perivascular region (arrows).
Figure 6. Co-localization of CD271 and CD56 in femoral
head bone marrow cells. Double immunofluorescence stain-
ing with (top row) CD271 and CD56 identified
CD2711CD561 cells in the bone-lining region and (middle
row) CD2711CD56– cells in the perivascular region. (Bottom
row) In the negative control panel, very small cells have no
DAPI staining (because of the absence of nuclei) but are
autofluorescent in the red and green channels corresponding
to cells, including red blood cells.
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in the perivascular region in the BM. Additionally, CD271
positivity was clearly detectable in the bone-lining region
as well (Figure 5). In contrast to CD271, CD56 was not
expressed in the perivascular regions of the BM compart-
ment, whereas it was expressed in the bone-lining region
(Figure 5). Furthermore, to confirm whether CD56 is coex-
pressed with CD271 in the bone-lining region, we costained
for CD271 and CD56 by immunofluorescence and found
CD56 to be expressed on all CD2711 cells on the bone sur-
face but not in the perivascular region (Figure 6). These
results show that CD2711CD561 cells are localized in the
bone-lining region, while CD2711CD56– cells are localized
in the perivascular region of the BM.
DISCUSSION
Cell-based therapies with culture-expanded MSCs have
emerged as one of the promising options for cartilage
repair. However, there is huge variation in the ability of
cartilage formation with these cells. Although several
attempts have been undertaken to overcome this varia-
tion,17,18,20 an optimal strategy has not yet been identified.
To overcome this challenge, in this study we took advan-
tage of the distinct spatial distribution of CTPs with chon-
drogenic potential in human BM and investigated whether
different harvest procedures influenced chondrogenic per-
formance among culture-expanded cells. In BM, CTPs
have been described to have 2 major localizations: a pre-
dominant sinusoidal niche that is typically found in more
central areas of the BM and a bone-lining niche in the
immediate vicinity of the endosteum.7,32 Patterson et al23
recently determined the location of CTPs within native
cancellous bone and their distribution between the marrow
space and trabecular surface. They showed that iliac can-
cellous bone contains 3-fold-more CTPs than iliac crest
BM aspirate and that 63.5% of all CTPs within iliac cancel-
lous bone resided on the trabecular surface. We showed
that the technique of BM harvest influences the proportion
of CTPs from these distinct tissue compartments, which
highly influences the chondrogenesis. Although cultured
MSCs derived from different parts of skeletal tissues,
including BM from the femur or iliac crest, display similar
characteristics,4,8,28 it is not clear whether they all contain
the same or different population of CTPs. We addressed
this question and showed that in femoral head and iliac
crest BM, cells in the bone-lining region have a higher
prevalence of CD45–CD2711CD561 staining while peri-
vascular cells have a CD45–CD2711CD56– profile.
Using donor-matched samples, we found that BM
obtained after rasping from the proximal femur is superior
to BM obtained with aspiration from the same bone in
terms of the prevalence of CD2711CD561 cells and in
the chondrogenic performance of culture-expanded MSCs
derived from the CTPs in these samples. However, these
data do not show that all CTPs in the rasp sample have
a CD2711CD561 profile. This is in line with other studies
showing that CTPs are present in higher prevalence on the
trabecular bone surface than in the central marrow space,4,6
thereby demonstrating that the sample-harvesting method
can highly influence the yield of CTPs and the chondrogenic
potential of their culture-expanded progeny (MSCs). These
findings also indicate that bone fragments as surgical
waste12 may likely contain highly chondrogenic bone-lining
cells.
FACS analysis on P3-cultured MSCs derived from
FACS-sorted CD2711CD561 and CD2711CD56– cells
revealed that these markers rapidly downregulate after
culturing and are hence absent in P3. According to these
results, CD271 and CD56 are markers to select different
subpopulations of CTPs, but there is no direct involvement
of these markers in the improved chondrogenic differentia-
tion of cultured MSCs derived from CD2711CD561 CTPs.
Nevertheless, the progeny of CD2711CD561 cells has
a higher colony-forming capacity as well as a higher chon-
drogenic differentiation potential than the progeny of
CD2711CD56– cells.
Total number of MSCs obtained after culture depends
on the number of CTPs initially present and the colony-
forming efficiency (ie, the probability that a cell that could
form a colony does form a colony under the conditions that
were used).26 Colony-forming efficiency can change with
the harvest, processing, and culture method. Furthermore,
vascular disruption leads to activation of thrombotic
factors, allowing blood clot formation and platelet activa-
tion in the operating or trauma site. Activated platelets
release growth and differentiation factors inducing MSC
activation.24 In this study, the harvest techniques used
in rasping may have resulted in greater exposure of
CTPs to activating agents associated with platelet degran-
ulation and clotting. This exposure may increase colony-
forming efficiency and result in a relative overestimation
of colony-founding cell (CFU-F) prevalence in the rasped
versus aspirated sourcing method. This represents a limita-
tion of the present study and must be tested in future
work.
Cox et al9 demonstrated that sample collection from long
bone fatty BM of the femur yielded 5-fold-more CD2711
cells than donor-matched aspirate from iliac crest. This
is in line with our observation that BM aspirated from
femur contained a higher prevalence of CD2711 cells.
The same group showed that collection of BM samples
with reamer-irrigator-aspirator (RIA), which involves rasp-
ing of femoral bone, releases even higher numbers of
CD2711 cells that are most likely not pericytes, thus indi-
cating their preferential bone-lining origin10 and making
this RIA-harvested material comparable with the rasped
BM in this study.
The fact that MSCs derived from BM obtained after
rasping more effectively differentiated into chondrocytes
in vitro than MSCs obtained from BM aspirate provides
strong evidence that rasped BM–derived MSCs can be
used as a source for cell therapy to repair cartilage. How-
ever, there was still high donor-to-donor variation in the
percentage of CD2711CD561 cells in the rasped BM.
This may be due to the difference in donor age,21 donor-
to-donor differences in the trabecular bone volume in the
rasping region, or varying levels of dilution of the BM
with blood during the harvest procedure.31 We observed
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donor-to-donor variation in the number of CD45–CD2711
CTPs in the BM obtained via aspiration and after rasping,
although there was no significant difference in the number
of CD45– cells or CD451 leucocytes in these samples.
Hence, it cannot be ignored that hemodilution of BM
with peripheral blood may be a reason for this variability
in CTP frequency among donors11,16 obtained by using
both harvest techniques.
Note that rasped BM in this study was harvested during
hip replacement surgery and hence can be potentially used
in an allogenic setup. To use these cells in an autologous
setup for traumatic injuries, new harvesting methods sim-
ilar to RIA have to be established. For this, further study is
needed to demonstrate the presence of similar bone-lining
CD561 cells in the midshaft of long bones.
Altogether, this study demonstrates that rasping and
aspiration are not only different as harvest methods but
also reveal different populations of CTPs. Culture-expanded
cells derived from BM obtained after rasping were more
chondrogenic than cells harvested by BM aspiration. The
increased prevalence of CD2711CD561 cells as opposed
to CD2711CD56– cells in the rasped population may be
related to this outcome. However, the mechanism by which
the CD2711CD561 population of cells contributes to
improved chondrogenesis has not been established. This
must be tested in future work.
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